Senate Bill 1425
117th Congress(2021-2022)
Stop STALLING Act
Introduced
Introduced in Senate on Apr 28, 2021
Origin Chamber
Senate
Type
Bill
Bill
The primary form of legislative measure used to propose law. Depending on the chamber of origin, bills begin with a designation of either H.R. or S. Joint resolution is another form of legislative measure used to propose law.
Bill Number
1425
Congress
117
Policy Area
Health
Health
Primary focus of measure is science or practice of the diagnosis, treatment, and prevention of disease; health services administration and funding, including such programs as Medicare and Medicaid; health personnel and medical education; drug use and safety; health care coverage and insurance; health facilities. Measures concerning controlled substances and drug trafficking may fall under Crime and Law Enforcement policy area.
No Senate votes have been held for this bill.
Summary
Stop Significant and Time-wasting Abuse Limiting Legitimate Innovation of New Generics Act or the Stop STALLING Act
This bill makes it an unfair method of competition to submit an objectively baseless petition to the Food and Drug Administration (FDA) in an attempt to interfere with a competitor's application for market approval of a drug.
The bill authorizes the Federal Trade Commission to sue an individual or entity that submits such a petition to the FDA. A party found liable in such a lawsuit shall be subject to civil penalties, such as a fine of up to $50,000 for each day that the FDA spent reviewing the baseless petition.
12/08/2021
Placed on Senate Legislative Calendar under General Orders. Calendar No. 179.
12/08/2021
Committee on the Judiciary. Reported by Senator Durbin without amendment. Without written report.
07/29/2021
Committee on the Judiciary. Ordered to be reported without amendment favorably.
04/28/2021
Read twice and referred to the Committee on the Judiciary.
04/28/2021
Introduced in Senate
Public Record
Record Updated
Jan 11, 2023 1:49:07 PM